Citius Oncology, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Citius Oncology, Inc. (Nasdaq: CTOR) is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma. The company offers LYMPHIR (denileukin diftitox-cxdl), a novel targeted immune therapy and biologic that binds to interleukin-2 (IL-2) receptors on malignant cells and regulatory T lymphocytes, inhibiting protein synthesis and inducing cell death. Founded in 2024 through a merger between Citius Pharmaceuticals' oncology subsidiary and TenX Keane Acquisition, Citius Oncology is headquartered in Cranford, New Jersey, and operates as a majority-owned subsidiary of Citius Pharmaceuticals, Inc., serving patients and providers primarily in the United States with plans for international expansion. In August 2024, the U.S. Food and Drug Administration approved LYMPHIR for adult patients with relapsed or refractory Stage I-III CTCL after at least one prior systemic therapy, marking the company's first commercial product and the only new FDA-approved systemic therapy for CTCL in over seven years. Recent developments include the U.S. commercial launch of LYMPHIR in December 2025 following shipment to national wholesalers; an exclusive commercialization agreement with EVERSANA to support the Q4 2025 launch; a $9.0 million registered direct offering closed in September 2025; and engagement of Jefferies in early 2025 to explore strategic alternatives such as partnerships, mergers, acquisitions, licensing deals, or joint ventures to enhance market penetration and growth opportunities including expanded indications and international licensing.
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)
Market Today: GDP Jumps, S&P Record; Novo Nordisk (NVO) Pill OK
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim